Orthocell

Orthocell EBITDA Growth YoY

The Year-over-Year EBITDA Growth of Orthocell (OCC.AX) as of Nov 5, 2026 is -31.54 %. In the previous year, Year-over-Year EBITDA Growth was -19.64 % — a change of 60.56% (lower).

EBITDA Growth YoY

-31.54 %

YoY

60.56%

Last updated:

Year-over-Year EBITDA Growth of Orthocell is 2026 -31.54 % . Year-over-Year EBITDA Growth of Orthocell was 2025 -19.64 % . It decreases by 60.56% lower compared to the previous year.

The Orthocell EBITDA Growth YoY history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA Growth YoY
Date
EBITDA Growth YoY
Jan 1, 2019
-6.03 AUD
Jan 1, 2020
-11.19 AUD
Jan 1, 2021
-23.23 AUD
Jan 1, 2022
1.24 AUD
Jan 1, 2023
10.54 AUD
Jan 1, 2024
-13.30 AUD
Jan 1, 2025
-19.64 AUD
Jan 1, 2026
-31.54 AUD
The Orthocell EBITDA Growth YoY history
YEAREBITDA Growth YoYYoY
-31.54 %+60.56%
-19.64 %+47.69%
-13.30 %-226.18%
10.54 %+750.07%
1.24 %-105.34%
-23.23 %+107.59%
-11.19 %+85.53%
-6.03 %-80.09%
-30.29 %+100.25%
-15.13 %+129.90%
-6.58 %-92.18%
-84.18 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Orthocell Stock analysis

What does Orthocell do? Orthocell Ltd develops and commercializes cell therapies and related technologies focused on regenerating mobility for patients with bone and soft tissue injuries. The company's products include CelGro, a collagen medical device using SMRT manufacturing for tissue reconstruction in dental and orthopedic applications, Striate+ for dental GBR, Remplir for peripheral nerve reconstruction, and SmrtGraft for tendon repair. Autologous cell therapy, particularly its tendon cell therapy in development in the United States, targets chronic tendon injuries through advanced injectable cellular therapy for cartilage and tendon regeneration. Orthocell's primary customers are healthcare providers and medical institutions requiring advanced tissue repair solutions. The company generates revenue through the sale of its medical devices and cell therapy products, with CelGro and related SMRT manufacturing processes forming a core part of its commercial portfolio. Its autologous tendon therapy development in the U.S. represents a key growth segment targeting chronic tendon injury treatments. The company's product portfolio is structured around regenerative medicine applications, with CelGro serving dental and orthopedic markets, Striate+ specifically for dental GBR, Remplir addressing nerve reconstruction needs, and SmrtGraft focused on tendon repair. Orthocell's commercial strategy emphasizes direct sales of these products to healthcare professionals and institutions seeking innovative solutions for tissue repair and regeneration. Orthocell is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Orthocell stock

Year-over-Year EBITDA Growth of Orthocell is -31.54 % in 2026.

On Eulerpool you can find the complete historical development of Year-over-Year EBITDA Growth Orthocell since 2006 – with annual values, charts, and detailed analysis.

EBITDA growth measures the percentage change in EBITDA compared to the prior year. It shows changes in operating cash earnings before capital structure effects.

To evaluate Year-over-Year EBITDA Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year EBITDA Growth.

Year-over-Year EBITDA Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year EBITDA Growth's Orthocell historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — Orthocell

All Key Metrics — Orthocell